When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
IGM Biosciences (IGMS) has filed to raise gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement.
The firm is focused on the development of engineered IgM antibodies as cancer treatments.
IGMS is a very early stage firm seeking public capital to advance its novel treatment candidates.
When we learn management’s valuation assumptions, I’ll provide an update.
Company & Technology
Mountain View, California-based IGM was founded in 1993 as Palingen and currently develops engineered IgM antibodies for the treatment of cancer patients.